Lipe & Dalton Exelixis, Inc. Transaction History
Lipe & Dalton
- $198 Million
- Q3 2024
Shares
2 transactions
Others Institutions Holding EXEL
# of Institutions
501Shares Held
244MCall Options Held
2.54MPut Options Held
2.29M-
Black Rock Inc. New York, NY33.5MShares$1.19 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.3MShares$1.04 Billion0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA25.4MShares$905 Million3.31% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.4MShares$547 Million0.63% of portfolio
-
State Street Corp Boston, MA11.4MShares$408 Million0.01% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $11.5B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...